MYCOPHENOLATE MOFETIL HYDROCHLORIDE - Generic Drug Details

What are the generic sources for mycophenolate mofetil hydrochloride and what is the scope of patent protection?

Mycophenolate mofetil hydrochloride is the generic ingredient in two branded drugs marketed by Roche Palo, Amneal, Bpi Labs, Meitheal, Mylan Labs Ltd, Onesource Specialty, Ph Health, Rising, and Zydus Pharms, and is included in nine NDAs. Additional information is available in the individual branded drug profile pages.

There is one drug master file entry for mycophenolate mofetil hydrochloride. Seven suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for MYCOPHENOLATE MOFETIL HYDROCHLORIDE

US Patents:	0
Tradenames:	2
Applicants:	9
NDAs:	9
Drug Master File Entries:	1
Finished Product Suppliers / Packagers:	7
Raw Ingredient (Bulk) Api Vendors:	27
Clinical Trials:	1,009
Patent Applications:	276
What excipients (inactive ingredients) are in MYCOPHENOLATE MOFETIL HYDROCHLORIDE?	MYCOPHENOLATE MOFETIL HYDROCHLORIDE excipients list
DailyMed Link:	MYCOPHENOLATE MOFETIL HYDROCHLORIDE at DailyMed

Recent Clinical Trials for MYCOPHENOLATE MOFETIL HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
City of Hope Medical Center	PHASE1
National Cancer Institute (NCI)	PHASE1
Mayo Clinic	PHASE2

See all MYCOPHENOLATE MOFETIL HYDROCHLORIDE clinical trials

Generic filers with tentative approvals for MYCOPHENOLATE MOFETIL HYDROCHLORIDE

Applicant	Application No.	Strength	Dosage Form
		500MG	INJECTABLE; INJECTION

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for MYCOPHENOLATE MOFETIL HYDROCHLORIDE

Drug Class

Antimetabolite Immunosuppressant

US Patents and Regulatory Information for MYCOPHENOLATE MOFETIL HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Rising	MYCOPHENOLATE MOFETIL HYDROCHLORIDE	mycophenolate mofetil hydrochloride	INJECTABLE;INJECTION	204043-001	Feb 28, 2017	AP	RX	No	No
Roche Palo	CELLCEPT	mycophenolate mofetil hydrochloride	INJECTABLE;INJECTION	050758-001	Aug 12, 1998	AP	RX	Yes	Yes
Zydus Pharms	MYCOPHENOLATE MOFETIL HYDROCHLORIDE	mycophenolate mofetil hydrochloride	INJECTABLE;INJECTION	204473-001	Aug 31, 2017	AP	RX	No	No
Meitheal	MYCOPHENOLATE MOFETIL HYDROCHLORIDE	mycophenolate mofetil hydrochloride	INJECTABLE;INJECTION	212130-001	Jan 15, 2021	AP	RX	No	No

Expired US Patents for MYCOPHENOLATE MOFETIL HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Roche Palo	CELLCEPT	mycophenolate mofetil hydrochloride	INJECTABLE;INJECTION	050758-001	Aug 12, 1998	4,753,935
Roche Palo	CELLCEPT	mycophenolate mofetil hydrochloride	INJECTABLE;INJECTION	050758-001	Aug 12, 1998	5,543,408

Market Dynamics and Financial Trajectory for Mycophenolate Mofetil Hydrochloride

Last updated: February 19, 2026

What Are the Key Market Drivers for Mycophenolate Mofetil Hydrochloride?

Mycophenolate mofetil hydrochloride (MMF) primarily treats organ transplant rejection prophylaxis and autoimmune diseases. Its global market is influenced by several factors:

• Growth in Organ Transplant Procedures
  The increasing number of kidney, liver, and heart transplants drives demand for immunosuppressants like MMF. In 2021, approximately 50,000 organ transplants occurred worldwide, with a compound annual growth rate (CAGR) of about 4.5% since 2010 (OPTN, 2022).

• Rising Autoimmune Disease Prevalence
  Conditions such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) see rising incidence, increasing the use of MMF. SLE affects around 20–70 per 100,000 globally, with higher rates in developed countries (Rees et al., 2017).

• Advancements in Immunosuppressive Regimens
  MMF became a standard component of immunosuppressive therapy post-transplant after FDA approval in 1995, replacing azathioprine in many protocols, which led to reduced rejection rates and improved graft survival.

• Patent Expiries and Generic Entry
  The originator drug entered patent expiry phases in the early 2010s, resulting in increased availability of generic versions. Generics typically reduce prices and expand market access.

• Regional Market Developments
  Emerging markets, notably in Asia-Pacific, exhibit rapid growth due to increased healthcare access, expanding transplant centers, and rising healthcare expenditure.

How Do Market Challenges Affect the Financial Outlook?

Key challenges include:

• Stringent Regulatory Requirements
  Regulatory agencies require extensive clinical data for approval of new indications and generic formulations, increasing R&D costs.

• Competitive Landscape
  Several generic manufacturers produce MMF, exerting price pressures. The competition affects profit margins, especially in markets with high generic penetration.

• Safety and Side Effect Profiles
  MMF's association with adverse effects like gastrointestinal issues and increased infection risk limits its use in some patient populations, potentially constraining market growth.

• Pricing and Reimbursement Policies
  Variability across regions impacts market size. Countries with strict price controls, such as parts of Europe, limit profitability for manufacturers.

What is the Financial Trajectory of MMF?

• Market Size and Forecasts
  The global mycophenolate mofetil market was valued at approximately USD 1.4 billion in 2021. It is projected to grow at a CAGR of about 6.2% until 2028, reaching USD 2.4 billion (Research and Markets, 2022).

• Revenue Breakdown

  • Branded vs. Generics: Generics account for over 65% of sales and are expected to increase dominance, especially in low-income regions.
  • Regional Distribution: North America currently holds about 45% of revenue, driven by high transplant rates and reimbursement systems. Asia-Pacific is the fastest-growing region.

• Profit Margin Trends
  Gross margins for original branded MMF are around 55–65%, but these diminish with generic competition, which can see margins below 30%.

• Key Manufacturers

  • Janssen Pharmaceuticals: Original patent holder. Revenue declined post-patent expiry as generics penetrated the market.
  • Sandoz, Teva, Mylan: Major producers of generic MMF, responsible for significant market share increases post-patent expiry.

• Pipeline and Innovation
  Few novel formulations or derivatives are in late-stage development. Most companies focus on optimizing existing formulations or expanding indication labels.

Are There Emerging Trends or Opportunities?

Yes. Notably:

• Biosimilar and Custom-Formulated Variants
  Companies explore biosimilar options and IV formulations to expand use cases.

• Expanded Indications
  Early-stage clinical trials for autoimmune diseases like multiple sclerosis (MS) could diversify revenue streams.

• Pricing Strategies
  Cost reduction through manufacturing efficiencies and biosimilar proliferation help sustain margins in the face of fierce competition.

Summary Table: Market Data Points

Metric	Value	Source
2021 Market Size	USD 1.4 billion	[Research and Markets, 2022]
Predicted Market Size (2028)	USD 2.4 billion	[Research and Markets, 2022]
CAGR (2022–2028)	6.2%	[Research and Markets, 2022]
% of Generics	65%+	[IMS Health, 2021]
North America Revenue Share	45%	[EvaluatePharma, 2022]

Key Takeaways

• The global MMF market is expanding steadily, driven by increasing transplant procedures and autoimmune disease prevalence.
• Patent expiries introduced significant generic competition, reducing prices and margin sustainability for originators.
• Emerging markets and regional healthcare expenditures offer growth prospects.
• Regulatory and safety concerns pose ongoing challenges but also opportunity in developing biosimilars and novel formulations.
• Revenue will increasingly rely on generics, with continued price competition influencing profitability trends.

FAQs

1. How has patent expiry impacted MMF sales?
Patent expiry in the early 2010s led to a surge in generic MMF production, significantly reducing prices and market share for original manufacturers, with generics now representing over 65% of sales.

2. Which regions are expected to see the fastest growth?
Asia-Pacific is the fastest-growing region due to increased transplant activities, expanding healthcare infrastructure, and rising autoimmune disease incidence.

3. Are there new indications for MMF in clinical development?
Early-stage research investigates MMF for indications such as multiple sclerosis and certain autoimmune conditions, potentially broadening its use.

4. What are the main safety concerns with MMF?
Risks include gastrointestinal discomfort, heightened infection susceptibility, and potential teratogenicity, which can limit use in certain patient groups.

5. How might biosimilars influence future market dynamics?
Biosimilars could further reduce pricing pressure, expand access, and introduce competition, especially if they demonstrate comparable efficacy and safety profiles.

---

References

[1] OPTN. (2022). Annual Data Report. United Network for Organ Sharing.
[2] Rees, F., et al. (2017). Systemic Lupus Erythematosus. The Lancet, 389(10085), 721–731.
[3] Research and Markets. (2022). Global Mycophenolate Mofetil Market Report.
[4] EvaluatePharma. (2022). World Market Outlook.